Get the Stockscreener App
10.09
0.49%
-0.05
After Hours:
10.09
Iteos Therapeutics Inc stock is traded at $10.09, with a volume of 1.54M.
It is down -0.49% in the last 24 hours and up +0.90% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$10.14
Open:
$10.15
24h Volume:
1.54M
Relative Volume:
0.96
Market Cap:
$386.18M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-3.2032
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
-0.79%
1M Performance:
+0.90%
6M Performance:
+33.82%
1Y Performance:
-42.21%
1-Day Range:
$10.09
$10.15
1-Week Range:
$10.09
$10.20
52-Week Range:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
10.09 | 447.90M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
What is iTeos Therapeutics Inc. company’s growth strategyGrow your portfolio with growth-oriented stocks - jammulinksnews.com
Is iTeos Therapeutics Inc. a growth stock or a value stockDiscover undervalued stocks ready to soar - jammulinksnews.com
What is the dividend policy of iTeos Therapeutics Inc. stockAchieve consistent double-digit returns - jammulinksnews.com
What catalysts could drive iTeos Therapeutics Inc. stock higher in 2025Build capital through low-risk investments - jammulinksnews.com
Is iTeos Therapeutics Inc. stock overvalued or undervaluedAchieve breakthrough results with expert guidance - jammulinksnews.com
How volatile is iTeos Therapeutics Inc. stock compared to the marketCapitalize on emerging investment opportunities - jammulinksnews.com
What makes iTeos Therapeutics Inc. stock price move sharplyMarket Forecast Report For 2025 - jammulinksnews.com
Price momentum metrics for iTeos Therapeutics Inc. explainedDaily Technical Forecast for Quick Gains - Newser
What are the technical indicators suggesting about iTeos Therapeutics Inc.Wealth Building Planner With Proven Results - jammulinksnews.com
Halper Sadeh Investigates iTeos Therapeutics, Veritex Holdings Merger Deals. - AInvest
Why iTeos Therapeutics Inc. stock attracts strong analyst attentionTrade Timing Strategy With Technical Data Explained - metal.it
Investigations into OLO, VBTX, ITOS, and WNS Shareholder Rights - AInvest
Reddit Investors Lose Big, Now Have Opportunity to Lead Fraud Lawsuit - AInvest
iTeos Therapeutics acquisition by Concentra Biosciences raises fiduciary duty concerns. - AInvest
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Visual trend scoring systems applied to iTeos Therapeutics Inc.Alpha Driven Watchlist With Alerts Published - metal.it
iTeos Therapeutics Inc. Added to High Probability Setup ListTriple Return Setup With Risk Control Explained - metal.it
These 10 Stocks are Winning Big - Insider Monkey
Is iTeos Therapeutics Inc. stock poised for growthReliable Investment Entry Signals Confirmed by Charts - metal.it
Using data tools to time your iTeos Therapeutics Inc. exitFree Early Entry Picks Before News Breakout - Newser
Can momentum traders help lift iTeos Therapeutics Inc.Trade Setup Builder with Custom Alerts - Newser
Price momentum metrics for iTeos Therapeutics Inc. explained Long-Term Safety Investment Analysis Report - Newser
How strong is iTeos Therapeutics Inc. company’s balance sheetInvest smarter with expert trading signals - jammulinksnews.com
Published on: 2025-07-27 21:40:11 - jammulinksnews.com
How Efficient Is iTeos Therapeutics Inc. at Controlling Operating CostsFree Deep Market Trend Analysis - Newser
Key External Factors That Drive iTeos Therapeutics Inc. Stock Price MovementsDaily Breakout Picks - Newser
Will iTeos Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsCapital Growth Picks - Newser
How iTeos Therapeutics Inc. stock performs during market volatilityFree Stock Selection with 300% Return - Newser
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, CIO, SNV on Behalf of Shareholders - GlobeNewswire Inc.
Wedbush Research Analysts Cut Earnings Estimates for ITOS - Defense World
iTeos Therapeutics Inc. Stock Analysis and ForecastRecord-breaking capital gains - PrintWeekIndia
Will iTeos Therapeutics Inc. stock split in the near futureHigh-yield investments - jammulinksnews.com
What drives iTeos Therapeutics Inc. stock priceExceptional growth trajectory - PrintWeekIndia
Q2 EPS Estimate for iTeos Therapeutics Lowered by Analyst - Defense World
SHAREHOLDER ALERT: Morris Kandinov Investigating AVDX, - GlobeNewswire
What analysts say about iTeos Therapeutics Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional
Is iTeos Therapeutics Inc. stock overhyped or has real potentialFree Predictions - jammulinksnews.com
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):